| Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | 詳細 |
| SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Brain Diseases; Brain metastases; Brain Neoplasms; Colonic Diseases; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Intestinal Diseases; Intestinal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms | 詳細 |
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | 詳細 |
| NEO-201 | NEO-201 | Phase 2 Clinical | National Cancer Institute, Precision Biologics Inc | Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms | 詳細 |
| Anti-CEA CAR T cell therapy (Shanghai GeneChem) | | Phase 2 Clinical | Shanghai Genechem Co Ltd | Colorectal Neoplasms; Liver Neoplasms | 詳細 |
| BMS-986490 | BMS-986490 | Phase 2 Clinical | Bristol-Myers Squibb Company | | 詳細 |
| LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | | 詳細 |
| Precemtabart tocentecan | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| MFE-23-CD3z T cell therapy (Cancer Research Technology) | | Phase 1 Clinical | Cancer Research Technology | | 詳細 |
| anti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics) | | Phase 1 Clinical | Shanghai Simcere Pharmaceutical Co Ltd | Colorectal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Small Intestine Cancers; Solid tumours; Stomach Neoplasms | 詳細 |
| 125-Iodine-labeled MFE-23 | | Phase 1 Clinical | Cancer Research UK | | 詳細 |
| anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Adenocarcinoma; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | 詳細 |
| CEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company) | | Phase 1 Clinical | Bristol-Myers Squibb Company | | 詳細 |
| 124I-M5A | | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | | 詳細 |
| IBI-3020 | IBI3020; IBI-3020 | Phase 1 Clinical | Xinda Biomedical Technology (Hangzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | 詳細 |
| SGN-CEACAM5C | PF-08046050; SGN-CEACAM5C; SAR445953; SAR-445953 | Phase 1 Clinical | Sanofi, Seagen Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms | 詳細 |
| EBC-129 | EBC129; EBC-129 | Phase 1 Clinical | Experimental Drug Development Centre | | 詳細 |
| GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | | 詳細 |